Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: A systematic review

被引:105
作者
Repantis, Dimitris [1 ]
Laisney, Oona [1 ]
Heuser, Isabella [1 ]
机构
[1] Charite, Dept Psychiat, D-14050 Berlin, Germany
关键词
Acetylcholinesterase inhibitors; Memantine; Neuroenhancement; Cognitive enhancement; Systematic review; Neuroethics; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; NMDA ANTAGONIST MEMANTINE; CHOLINERGIC MODULATION; RECEPTOR-ACTIVITY; EPISODIC MEMORY; DONEPEZIL; YOUNG; DISEASE; SLEEP; ENHANCEMENT;
D O I
10.1016/j.phrs.2010.02.009
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
The term neuroenhancement refers to improvement in the cognitive, emotional and motivational functions of healthy individuals through, inter alia, the use of drugs. Of known interventions, psychopharmacology provides readily available options, such as the anti-dementia drugs, e.g. acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine) and memantine. Based on a systematic review we found that expectations about the potential of these drugs exceed their actual effects, as has been demonstrated in randomised controlled trials. Both single and repeated dose trials were included in the systematic review, however repeated dose trials have only been conducted for donepezil. In six small trials lasting 14-42 days, the following results emerged: donepezil improved the retention of training on complex aviation tasks and verbal memory for semantically processed words. In one study episodic memory was improved, whereas in others it remained unaffected by donepezil. In a sleep deprivation trial, donepezil reduced the memory and attention deficits resulting from 24 h of sleep deprivation. Two studies reported even transient negative effects. Regarding the safety profile of donepezil, these studies found that it was rather well tolerated. In any case, since large longitudinal studies are not available no conclusions can be drawn. Seven small studies about the effects of a single dose of memantine, and one study with a single dose of rivastigmine have been reported. Again, these studies are not adequate to answer our research question. If, as here and elsewhere suggested, the concept of pharmaceutical neuroenhancement is not to be rejected in principle, the decision of healthy individuals to take drugs for the purpose of neuroenhancement should be based on exhaustive information. At the moment, the research that would support or oppose the use of acetylcholinesterase inhibitors and memantine for neuroenhancement by healthy individuals has not yet been performed. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:473 / 481
页数:9
相关论文
共 41 条
[1]
[Anonymous], 1998, A Compendium of Neuropsychological Tests
[2]
Neuropsychological test performance in healthy elderly volunteers before and after donepezil administration - A randomized, controlled study [J].
Beglinger, LJ ;
Tangphao-Daniels, O ;
Kareken, DA ;
Zhang, L ;
Mohs, R ;
Siemers, ER .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2005, 25 (02) :159-165
[3]
Neuropsychological test performance in healthy volunteers before and after donepezil administration [J].
Beglinger, LJ ;
Gaydos, BL ;
Kareken, DA ;
Tangphao-Daniels, O ;
Siemers, ER ;
Moh, RC .
JOURNAL OF PSYCHOPHARMACOLOGY, 2004, 18 (01) :102-108
[4]
Birks J, 2006, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001190.pub3, 10.1002/14651858.CD001190.pub2]
[5]
Cholinergic Augmentation Modulates Visual Task Performance in Sleep-Deprived Young Adults [J].
Chuah, Lisa Y. M. ;
Chee, Michael W. L. .
JOURNAL OF NEUROSCIENCE, 2008, 28 (44) :11369-11377
[6]
Donepezil Improves Episodic Memory in Young Individuals Vulnerable to the Effects of Sleep Deprivation [J].
Chuah, Lisa Y. M. ;
Chong, Delise L. ;
Chen, Annette K. ;
Rekshan, William R., III ;
Tan, Jiat-Chow ;
Zheng, Hui ;
Chee, Michael W. L. .
SLEEP, 2009, 32 (08) :999-1010
[7]
Botox for the brain: enhancement of cognition, mood and pro-social behavior and blunting of unwanted memories [J].
de Jongh, Remoud ;
Bolt, Ineke ;
Schermer, Maartje ;
Olivier, Berend .
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2008, 32 (04) :760-776
[8]
Disease mongering: expanding the boundaries of treatable disease [J].
Doran, E. ;
Henry, D. .
INTERNAL MEDICINE JOURNAL, 2008, 38 (11) :858-861
[9]
Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects [J].
Dumont, GJH ;
de Visser, SJ ;
Cohen, AF ;
van Gerven, JMA .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (05) :495-510
[10]
Neurocognitive enhancement: what can we do and what should we do? [J].
Farah, MJ ;
Illes, J ;
Cook-Deegan, R ;
Gardner, H ;
Kandel, E ;
King, P ;
Parens, E ;
Sahakian, B ;
Wolpe, PR .
NATURE REVIEWS NEUROSCIENCE, 2004, 5 (05) :421-425